Procedure Deep-Dive · November 20, 2026
Thalassemia and Cosmetic Surgery: Thalassemia Trait, Anemia, Transfusions, Iron Overload, Splenectomy, Blood Clots, Tummy Tucks, Liposuction, and Breast Surgery
Thalassemia trait is one of the most common inherited blood findings in Los Angeles, and it is routinely mistaken for iron deficiency on a pre-op lab panel. The serious forms bring transfusions, iron in the heart, a missing spleen, and a clotting tendency that most body-contouring plans never account for. Here is how to read the numbers, what a surgeon should ask, and when a hematologist belongs on the team.
By The Editorial Desk
18 min read

She is 36, her family came to Los Angeles from Tehran when she was a child, and she wants a tummy tuck with liposuction of the flanks. Her pre-op blood work comes back with a hemoglobin of 10.9 and red cells that are small and pale. The nurse calls with a plan: start iron pills, recheck in six weeks, and if the number has not come up, the surgery date moves. Six weeks later the hemoglobin is 10.8. Her stomach hurts from the iron. Nobody has asked whether anyone else in her family has "low blood," and nobody has looked at the fact that her red cell count was actually above normal. She has beta thalassemia trait. She has had it her whole life. Iron was never going to change the number.
That scene plays out in cosmetic practices all the time, and it is the mild end of the story. At the other end are adults with transfusion-dependent thalassemia who have spent their lives in infusion chairs, carry iron in their hearts and livers, may have had their spleens removed, and now want the same breast reductions, tummy tucks, and liposuction anyone else wants. Both groups can usually have surgery. They need very different plans. Our general piece on anemia and blood loss before and after cosmetic surgery covers low hemoglobin in broad terms. This one is about the inherited condition that explains a surprising share of the low numbers surgeons see, and the specific risks that come with its more serious forms.
What thalassemia is, and why it shows up so often in Los Angeles
The short answer: thalassemia is a group of inherited conditions in which the body makes too little of one of the protein chains that build hemoglobin, producing small red cells and anywhere from no symptoms at all to lifelong transfusion dependence, and it is common in people with Mediterranean, Middle Eastern, South Asian, Southeast Asian, Chinese, and African ancestry, which describes a large part of the patient population in Southern California.
Adult hemoglobin is built from two kinds of protein chains, alpha and beta. Thalassemia is named for the chain that falls short. In beta thalassemia, one or both beta globin genes are faulty. In alpha thalassemia, one or more of the four alpha globin genes are missing or faulty. Either way, the red cells that come off the production line are smaller and carry less hemoglobin than normal, and in the more severe forms, the unbalanced chains damage the cells before they ever leave the bone marrow.
The World Health Organization has long estimated that around 5 percent of the world's population carries a significant inherited hemoglobin variant, a figure that includes thalassemia genes and the sickle cell gene. Carrier rates are highest in a belt that runs from the Mediterranean through the Middle East and the Indian subcontinent into Southeast Asia and southern China. Greek, Italian, Cypriot, Armenian, Iranian, Arab, Indian, Pakistani, Filipino, Vietnamese, Thai, Cambodian, Laotian, and Chinese families all carry these genes at meaningful rates, as do many families of African descent. A surgeon practicing in Los Angeles, Orange County, or the San Gabriel Valley sees thalassemia carriers every week, whether or not anyone has written the word in the chart.
The conditions sort into practical tiers, and the tier matters far more than the label:
- Silent carrier and trait (also called thalassemia minor). One faulty beta gene, or one or two missing alpha genes. Mild anemia or none, small red cells, no symptoms. This is the overwhelming majority of people with a thalassemia gene.
- Non-transfusion-dependent thalassemia (NTDT). Beta thalassemia intermedia, hemoglobin E/beta thalassemia in some patients, and hemoglobin H disease (three missing alpha genes). Moderate chronic anemia, occasional transfusions, an enlarged spleen, and, importantly for surgery, a higher tendency to form clots.
- Transfusion-dependent thalassemia (TDT). Beta thalassemia major and severe forms of hemoglobin E/beta thalassemia. Regular transfusions, usually every two to five weeks for life, plus medication to remove the iron those transfusions deposit.
There is a close cousin worth naming. Sickle cell disease is a different change in the beta chain, and some people inherit one sickle gene and one beta thalassemia gene, a combination called sickle beta thalassemia that behaves like sickle cell disease and is managed under those rules. Our piece on sickle cell disease and cosmetic surgery covers that group. If your hemoglobin report lists hemoglobin S anywhere, that is the article for you, not this one.
Thalassemia trait on a pre-op lab panel: not iron deficiency, not a reason to cancel
The short answer: thalassemia trait produces a mildly low hemoglobin with very small red cells and a normal or high red cell count, it is stable for life, and it should be recognized as a baseline rather than treated with iron or used as a reason to postpone surgery indefinitely, while the real job is to make sure the operation is planned around a smaller cushion for blood loss.
The confusion is understandable. Iron deficiency and thalassemia trait both produce small red cells, a low MCV (mean corpuscular volume) on the blood count. But the patterns differ in ways any surgeon can read on the same lab sheet. In iron deficiency, the red cell count usually falls along with the hemoglobin, the variation in cell size (RDW) climbs, and ferritin, the body's iron storage marker, is low. In thalassemia trait, the MCV is often strikingly low, sometimes in the 60s, while the red cell count is normal or even above normal and ferritin is normal. A quick bedside calculation called the Mentzer index (MCV divided by the red cell count) tends to fall below 13 in trait and above 13 in iron deficiency. It is a screening clue, not a diagnosis, but it is the kind of clue that should prompt one more test before anyone writes a prescription for iron.
That test is a hemoglobin evaluation (electrophoresis or high-performance liquid chromatography). In beta thalassemia trait it typically shows an elevated hemoglobin A2, usually above about 3.5 percent. Alpha thalassemia trait is trickier: the electrophoresis is usually normal in adults, and the diagnosis rests on DNA testing or on excluding everything else. Two traps follow from this. First, iron deficiency can mask the raised A2 of beta trait, so a patient can have both conditions at once, and the trait only becomes visible after the iron is replaced. Second, a patient with alpha trait can go years being told she is "a little anemic" with no explanation.
Why does this matter for cosmetic surgery? Three reasons.
Unnecessary iron. Iron supplements do not raise hemoglobin in trait unless the patient is also iron deficient. Weeks of iron cause stomach upset and constipation for no benefit, and a habit of taking iron indefinitely, in someone who absorbs it normally, is not harmless. An IV iron infusion ordered to "get the number up" before a tummy tuck is a misuse of a useful treatment when ferritin is already normal. Our supplements before surgery stop list is a good reminder that more pills before surgery is not automatically safer.
The surgery date should not be held hostage to a number that cannot move. A trait carrier with a hemoglobin of 11 is not "anemic" in the sense of having a fixable deficit. That is her normal. Delaying surgery for months while waiting for a stable genetic value to improve is a planning error. The right question is not "how do we fix this?" but "is this baseline adequate for this operation?"
The cushion is smaller. Here is the part that does matter. A patient who starts at 11 has less room to absorb blood loss than one who starts at 14. That changes the arithmetic for the operations that lose the most blood: large-volume liposuction, combined tummy tuck and liposuction, mommy makeovers, and long combined procedures. It does not usually change the arithmetic for a breast augmentation or an eyelid lift.
Practical points for a trait carrier planning body surgery: ask the surgeon what blood loss they expect for the planned procedure; ask whether the plan should be staged into two shorter operations rather than one long one; make sure ferritin is checked so any true iron deficiency on top of the trait is treated properly; and expect postoperative recovery of the hemoglobin to return to the trait baseline, not above it. A patient told after surgery that her hemoglobin "has not recovered" when it is sitting exactly where it was before surgery is being measured against the wrong standard.
One more trait-specific point, for anyone planning a pregnancy before a mommy makeover: if both partners carry a thalassemia gene, each pregnancy carries a chance of a child with a serious form. The American College of Obstetricians and Gynecologists recommends hemoglobin evaluation and partner testing in exactly these situations. That conversation belongs with an obstetrician or genetic counselor, but a cosmetic consultation is sometimes the first place a patient hears the word "trait," so it is worth saying.
"A thalassemia carrier with a hemoglobin of 11 does not have a deficit to fix. She has a baseline to plan around. The mistake is treating a genetic number like a vitamin problem.
"
Transfusion-dependent thalassemia: iron in the heart, the liver, and the glands
The short answer: adults with transfusion-dependent thalassemia can have elective cosmetic surgery, but only after the hematologist confirms that iron levels in the heart and liver are controlled, the endocrine complications of iron overload are known and treated, and the blood bank has time to find compatible blood, which means planning weeks ahead, not days.
Every unit of transfused blood brings roughly 200 to 250 milligrams of iron, and the body has no active way to excrete it. Someone transfused every three or four weeks for decades accumulates enormous iron stores unless that iron is pulled out with chelating drugs: deferoxamine (an infusion under the skin), deferasirox (a tablet), or deferiprone (a tablet). Untreated or undertreated, the iron settles in the liver, the heart, and the endocrine glands. Our piece on hemochromatosis and cosmetic surgery covers inherited iron overload, which damages the same organs. The difference here is that phlebotomy, the simple treatment for hemochromatosis, is not an option for someone who is already anemic.
The Thalassemia International Federation's guidelines lay out the monitoring that thalassemia centers use, and a surgeon should ask for the results rather than relying on the patient's memory:
- Cardiac iron. Measured by a specialized MRI sequence (cardiac T2-star). A value below 20 milliseconds indicates iron in the heart muscle, and values below 10 indicate a high risk of heart failure and dangerous rhythm problems. Iron cardiomyopathy has historically been the leading cause of death in thalassemia major. For an anesthesiologist, a recent cardiac T2-star and echocardiogram are as important as any lab value.
- Liver iron and liver health. Measured by MRI as well. Many adults transfused before routine donor screening in the early 1990s were exposed to hepatitis C, and some have cirrhosis. Our piece on fatty liver disease and cosmetic surgery explains what liver scarring does to bleeding, drug handling, and healing.
- Endocrine glands. Iron overload causes diabetes, an underactive thyroid, underactive parathyroid glands (which lowers calcium), low sex hormones, and, in some patients, an underactive adrenal response to stress. Each matters on the day of surgery: low calcium can cause rhythm problems and muscle spasm, an inadequate adrenal response can cause dangerous low blood pressure under anesthesia, and undiagnosed diabetes impairs healing. Our piece on Addison's disease and cosmetic surgery covers stress-dose steroids in detail.
- Bones. Osteoporosis is extremely common in adults with thalassemia, driven by marrow expansion, low sex hormones, and the disease itself. That affects positioning and some procedure choices, as our piece on osteoporosis and cosmetic surgery explains.
A detail that trips up even careful practices: the hemoglobin A1c, the standard diabetes screening test, is unreliable in thalassemia and in anyone recently transfused, because it depends on the lifespan of the patient's own red cells. A normal A1c in a thalassemia patient does not rule out diabetes. Fasting glucose, glucose tolerance testing, or fructosamine are better guides, as our piece on blood sugar and cosmetic surgery discusses.
The blood bank problem. Patients who have received hundreds of transfusions often develop antibodies against minor red cell markers (alloantibodies). That makes finding compatible blood slower and sometimes difficult. Thalassemia centers usually transfuse blood matched for extended red cell markers for this reason. For elective surgery, the practical consequence is simple: the hospital blood bank needs the patient's antibody history and a sample well before the operation, ideally coordinated with the patient's own thalassemia center. An outpatient surgery center with no on-site blood bank and no relationship to the patient's hematologist is the wrong venue for a large body-contouring procedure in this group. Our piece on outpatient facility accreditation explains what to ask about any facility.
Timing around transfusions. Most hematologists will schedule elective surgery shortly after a routine transfusion, when hemoglobin is at its peak, and will set a target for the day of surgery. The guidelines generally aim for a pretransfusion hemoglobin of around 9.5 to 10.5 grams per deciliter in transfusion-dependent patients; for a major operation, the hematologist may transfuse to a higher level beforehand.
Chelation medications. These also need a plan. Deferiprone can cause a sudden, severe drop in infection-fighting white cells (agranulocytosis), which is why patients on it have frequent blood counts; a surgeon should know the most recent count. Deferasirox can affect kidney function, which makes anti-inflammatory painkillers a poor choice. Whether to hold chelation around surgery is a decision for the hematologist, not the surgical team.
Newer treatments. Luspatercept, approved by the FDA in 2019 for adults with transfusion-dependent beta thalassemia, reduces transfusion needs in many patients but carries warnings about blood clots and high blood pressure. Gene therapies, betibeglogene autotemcel (approved in 2022) and exagamglogene autotemcel (approved in 2024), can end transfusion dependence for many patients, but they require high-dose chemotherapy conditioning beforehand. A patient in the first year or so after gene therapy is still recovering blood counts and immunity, and cosmetic surgery should wait until the transplant team says otherwise. Our piece on cosmetic surgery after chemotherapy covers the general logic of waiting for counts to recover.
The missing spleen and the clotting tendency nobody mentions
The short answer: many adults with moderate or severe thalassemia have had their spleens removed or have an enlarged spleen, and both thalassemia itself and splenectomy raise the risk of blood clots, so a long tummy tuck or combined procedure in a splenectomized thalassemia patient deserves a deliberate clot-prevention plan and a low threshold for treating any postoperative fever as an emergency.
Thalassemia is usually thought of as a bleeding-adjacent problem because of the anemia. It is actually a clotting problem. Damaged red cells expose fats on their surface that activate the clotting system, platelets are more active, and after splenectomy, platelet counts often run high for years. A large international study of nearly 9,000 thalassemia patients, published in Thrombosis and Haemostasis in 2006, found clotting events in around 1 percent of patients with thalassemia major and around 4 percent of those with thalassemia intermedia, with splenectomy and older age among the strongest risk factors. Later work in non-transfusion-dependent patients found that splenectomized patients with high platelet counts and many circulating abnormal red cells carried the highest risk, including silent strokes on brain imaging.
For a cosmetic surgeon, that translates into concrete steps. A thalassemia patient who has had a splenectomy, or who has thalassemia intermedia or hemoglobin H disease, should be treated as being at elevated baseline clot risk when calculating a Caprini score, before anything about the operation is added. Long combined procedures, abdominoplasty in particular, already sit high on the clot-risk table. Our piece on blood clots after plastic surgery explains the scoring and the prevention options, and our piece on Factor V Leiden and cosmetic surgery walks through how surgeons trade clot prevention against hematoma risk. The same trade-off applies here, with the added complexity that some of these patients also have liver disease affecting their clotting proteins.
Several other items deserve explicit discussion:
- Estrogen. Combined birth control pills and hormone therapy add clot risk on top of an already elevated baseline. The surgeon, the gynecologist, and the hematologist should agree on whether to pause them and what contraception to use instead.
- Tranexamic acid. This bleeding-reducing drug has become common in body contouring and facial surgery, as our piece on tranexamic acid in cosmetic surgery explains. The evidence in general surgical populations has not shown a clear increase in clots, but patients with a known clotting tendency were often excluded from those studies. In a splenectomized thalassemia patient, the decision to use it deserves a conversation with the hematologist rather than a default order.
- Pulmonary hypertension. High pressure in the lung arteries is a recognized complication of non-transfusion-dependent thalassemia, especially after splenectomy, and it makes anesthesia riskier. An echocardiogram within the past year is a reasonable request before a major operation.
- Infection after splenectomy. People without a working spleen are vulnerable to overwhelming bloodstream infections from bacteria such as pneumococcus and meningococcus. Their vaccines should be current. A fever after surgery in someone without a spleen is not something to watch overnight at home. Our piece on fever after plastic surgery explains the usual low-grade fevers after surgery; for asplenic patients, the threshold for calling and being seen is lower.
- Gallstones and old scars. Chronic red cell breakdown produces pigment gallstones, so many adults with thalassemia have had their gallbladders out, sometimes along with the spleen through an open incision. Old upper abdominal scars can affect the blood supply of a tummy tuck flap, as our piece on old abdominal surgery scars and tummy tucks explains.
Procedure by procedure: liposuction, tummy tucks, breast surgery, and the face
The short answer: the more blood an operation is expected to lose and the longer it runs, the more a thalassemia diagnosis changes the plan, so large-volume liposuction, combined tummy tuck procedures, and Brazilian butt lifts need the most preparation, while breast augmentation, eyelid surgery, and injectables usually need little beyond an accurate history.
Liposuction. Blood loss in liposuction rises with the volume removed, and tumescent technique reduces it considerably but does not eliminate it. For a trait carrier with a hemoglobin around 11, a modest liposuction is usually straightforward. For a patient with thalassemia intermedia who lives at 8 or 9, a large-volume case is a different proposition, and the surgeon should either limit the volume, stage the procedure, or plan a transfusion with the hematologist in advance. Tumescent lidocaine dosing is calculated on body weight, and patients with liver disease from old hepatitis or iron overload clear it more slowly, a point our piece on lidocaine toxicity in tumescent liposuction covers.
Tummy tucks and mommy makeovers. These combine blood loss, long operating time, and the highest clot risk in cosmetic surgery. In patients with non-transfusion-dependent or transfusion-dependent thalassemia, especially after splenectomy, a hospital setting with a blood bank, a written clot-prevention plan, and a hematologist who has signed off are reasonable conditions. Staging a mommy makeover into two operations, breasts first and abdomen later or the reverse, is often the safer choice. Healing problems also matter: low oxygen-carrying capacity, diabetes from iron overload, and in some patients chronic leg ulcers all signal tissue that heals more slowly. Our piece on wound dehiscence after cosmetic surgery explains how surgeons reduce that risk.
Brazilian butt lift. Fat grafting to the buttocks involves substantial liposuction plus long operating time and a prone position. The fat embolism risk that dominates our BBL safety protocols piece is not changed by thalassemia, but the blood loss and clot considerations are added to it. A patient with a serious form of thalassemia should be wary of any practice that treats BBL as a quick outpatient procedure.
Breast surgery. Breast reduction involves meaningful blood loss and is often combined with liposuction of the sides of the chest; the same blood-loss arithmetic applies, on a smaller scale than a tummy tuck. Breast augmentation typically loses little blood and is usually manageable for trait carriers without special measures. For women with transfusion-dependent thalassemia and low sex hormones from iron in the pituitary gland, breast development may have been incomplete, and they sometimes seek augmentation for that reason. That is a legitimate goal, but the hormonal picture and bone density should be understood first.
The face. In thalassemia that was not well treated in childhood, the bone marrow expands to compensate for the anemia, widening the cheekbones and upper jaw and making the forehead more prominent. Modern transfusion programs prevent most of this, but some adults, particularly those who grew up where regular transfusion was not available, carry these changes and seek facial contouring or jaw surgery. Bone that has been filled with active marrow can bleed more during cutting, and an overgrown upper jaw can make the anesthesiologist's job of securing the airway harder. Our piece on orthognathic jaw surgery versus jawline procedures is a good place to start for anyone considering skeletal changes. Fillers and toxin injections, by contrast, raise few thalassemia-specific concerns, aside from bruising in patients with low platelets or liver disease.
Where you have surgery. For the serious forms of thalassemia, surgery should happen where the hematologist and the blood bank are reachable. Traveling abroad for a body-contouring procedure, away from a thalassemia center, a matched blood supply, and the doctors who know your antibody history, adds risk that is hard to justify. Our piece on the true cost of plastic surgery tourism covers the general case; for this group, the case is stronger.
The honest summary
Thalassemia is two very different stories under one name. For the large majority of people who carry it, thalassemia trait is a lifelong, harmless laboratory finding that happens to look like iron deficiency. The most useful thing a surgeon can do is recognize it: check ferritin, look at the red cell count, order a hemoglobin evaluation when the pattern fits, and stop prescribing iron that cannot fix a genetic number. Then plan the operation around a smaller blood-loss cushion, which may mean limiting liposuction volume or staging a combined procedure, rather than postponing surgery while waiting for a stable number to change.
For adults with transfusion-dependent or non-transfusion-dependent thalassemia, elective surgery is possible but should be a team effort. The hematologist needs to confirm that iron in the heart and liver is under control, that diabetes, thyroid, parathyroid, and adrenal problems are known and treated, and that the blood bank has the antibody history and time to find compatible blood. The surgical team needs to treat thalassemia, and especially splenectomy, as a clotting risk factor, to think carefully before ordering tranexamic acid or continuing estrogen, and to treat any fever in an asplenic patient as urgent. A hospital with a blood bank, near the patient's thalassemia center, is the right venue for the larger operations.
For patients, the most valuable step is bringing the right paperwork: your hemoglobin evaluation or DNA result, your usual hemoglobin, any antibody card from your transfusion center, your most recent cardiac and liver MRI results, and a list of every medication including chelators. Keep your own copies, for the reasons our piece on medical records after cosmetic surgery explains. And if a surgeon hears "thalassemia" and either waves it away or cancels without explanation, neither response is a plan. A second consultation with a surgeon who will pick up the phone and call your hematologist is worth the extra appointment.